Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 231

Sort by

Sort Order Select

Journal Articles

A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML

Blood (2021) 137 (24): 3403–3415.

https://doi.org/10.1182/blood.2020009023

Published: 2021

Includes: Supplemental data

Journal Articles

JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation

Lauren K. Meyer, Katherine C. Verbist, Sabrin Albeituni, Brooks P. Scull, Rachel C. Bassett, Alexa N. Stroh, Heather Tillman, Carl E. Allen, Michelle L. Hermiston, Kim E. Nichols

Blood (2020) 136 (6): 657–668.

https://doi.org/10.1182/blood.2020006075

Published: 2020

Includes: Supplemental data

Journal Articles

Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant–associated ALCL

Blood (2020) 135 (5): 360–370.

https://doi.org/10.1182/blood.2019001904

Published: 2020

Includes: Supplemental data

Journal Articles

HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms

Blood (2020) 135 (3): 191–207.

https://doi.org/10.1182/blood.2019895326

Published: 2020

Includes: Supplemental data

Journal Articles

Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade

Bjoern Chapuy, Chip Stewart, Andrew J. Dunford, Jaegil Kim, Kirsty Wienand, Atanas Kamburov, Gabriel K. Griffin, Pei-Hsuan Chen, Ana Lako, Robert A. Redd, Claire M. Cote, Matthew D. Ducar, Aaron R. Thorner, Scott J. Rodig, Gad Getz, Margaret A. Shipp

Blood (2019) 134 (26): 2369–2382.

https://doi.org/10.1182/blood.2019002067

Published: 2019

Includes: Supplemental data

Journal Articles

Prognostic Impact of Chromosomal Abnormalities and Copy Number Alterations Among Adults with B-Cell Precursor Acute Lymphoblastic Leukaemia Treated on UKALL14

Anthony V. Moorman, Ellie Butler, Emilio Barretta, Amy A. Kirkwood, MSc, Claire Schwab, PhD, Thomas Creasey, MBBS, Daniel A. Leongamornlert, PhD, Elli Papaemmanuil, PhD, Pip Patrick, PhDMSc,MA, Laura Clifton-Hadley, PhDBSc, Bela Wrench, MBBS, MD MRCP, FRCPath, Tobias F Menne, MD PhD FRCPath, Andrew K McMillan, FRCP, Christine J. Harrison, PhD FRCPath, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, David I Marks, MBBS, PhD FRCPath, Adele K. Fielding, MBBS,PhDFRCP,FRCPath

Blood (2019) 134 (Supplement_1): 288.

https://doi.org/10.1182/blood-2019-123642

Published: 2019

Journal Articles

The Validation of the BCR/ABL1 -like Predictor across Laboratories Shows Reproducibility of Results

Sabina Chiaretti, MD PhD, Taherinasab Akram, Canichella Martina, Monica Messina, Alfonso Piciocchi, Cyril Šálek, MD PhD, Katerina Machova, Katerina Blagoevova, Jordi Ribera, PhD, Josep-Maria Ribera, MD PhD, Manja Meggendorfer, PhD, Claudia Haferlach, MD, Anna Guarini, PhD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 5211.

https://doi.org/10.1182/blood-2019-122116

Published: 2019

Journal Articles

Progressive Down Regulation of JAK-STAT, Cell Cycle, and ABC Transporter Genes in CD34+/Lin- Cells of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients at Diagnosis Vs. 12 Months of Nilotinib Treatment Vs. Healthy Subjects

Blood (2019) 134 (Supplement_1): 5034.

https://doi.org/10.1182/blood-2019-125595

Published: 2019

Journal Articles

Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia

Shruti Bhatt, PhD, Marissa Pioso, Elyse Ann Olesinski, Binyam Yilma, Leutz Buon, Sophia Adamia, PhD, Holly Zhu, Jeremy Ryan, Youzhen Wang, Morris Erick, Ensar Halilovic, David M. Weinstock, MD, Jacqueline S Garcia, MD, Anthony Letai

Blood (2019) 134 (Supplement_1): 2551.

https://doi.org/10.1182/blood-2019-131101

Published: 2019

Journal Articles

Integration of Genetic, Transcriptomic, and Immune Profiles Reveals Genomically-Distinct Populations in Low-Grade Lymphomas

Keenan T. Hartert, PhD, Kerstin Wenzl, PhD, Jordan Krull, Michelle Manske, MS, BS, Vivekananda Sarangi, Melissa C Larson, Theodora Anagnostou, MD, Ellen D. McPhail, MD, Brian K. Link, MD, Stephen M Ansell, MD PhD, James R. Cerhan, MD PhD, Dragan Jevremovic, MD PhD, Anne J Novak, PhD

Blood (2019) 134 (Supplement_1): 2764.

https://doi.org/10.1182/blood-2019-128803

Published: 2019

Journal Articles

HTLV-1 Dysregulates IL-6 and IL-10-JAK/STAT Signaling and Induces Leukemia/Lymphoma of Mature CD4+ T Cells with Regulatory T-Cell-like Signatures

Yusuke Higuchi, MD, Jun-ichirou Yasunaga, MD PhD, Yu Mitagami, PhD, Koichi Ohshima, MD PhD, Masao Matsuoka, MD PhD

Blood (2019) 134 (Supplement_1): 1516.

https://doi.org/10.1182/blood-2019-125546

Published: 2019

Journal Articles

Dual Driver Mutant BCR-ABL1-Negative Myeloid Neoplasms: Multicenter Clinicopathologic and Genomic Analysis

Zachary D. Epstein-Peterson, MD, Joseph Tripodi, Maria E Arcila, MD, Filiz Sen, MD, Vesna Najfeld, PhD, John Mascarenhas, MD, Ronald Hoffman, MD, Rajit K. Rampal, MD, PhD

Blood (2019) 134 (Supplement_1): 4173.

https://doi.org/10.1182/blood-2019-125379

Published: 2019

Journal Articles

Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL

Christian Hurtz, PhD, Gerald Wertheim, MD, PhD, Joseph Patrick Loftus, BS, Daniel Blumenthal, PhD, Anne Lehman, Yong Li, Bryan Manning, Katherine D Cummins, BMBS, Janis K Burkhardt, PhD, Alexander E. Perl, MD, Martin Carroll, MD, Sarah K. Tasian, MD

Blood (2019) 134 (Supplement_1): 747.

https://doi.org/10.1182/blood-2019-123514

Published: 2019

Journal Articles

Autocrine LTA signaling drives NF-κB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma

Linda von Hoff, Eva Kärgel, Vedran Franke, Erik McShane, Kathrin W. Schulz-Beiss, Giannino Patone, Nikolai Schleussner, Marina Kolesnichenko, Norbert Hübner, Oliver Daumke, Matthias Selbach, Altuna Akalin, Stephan Mathas, Claus Scheidereit

Blood (2019) 133 (13): 1489–1494.

https://doi.org/10.1182/blood-2018-08-871293

Published: 2019

Includes: Supplemental data

Journal Articles

A Case of CCDC6-RET Fusion Mutation in Adult Acute Lymphoblastic Leukemia (ALL), a Known Activating Mutation Unreported in ALL

Mateo Mejia Saldarriaga, MD, Amir Steinberg, MD, Adam F. Binder, MD

Blood (2018) 132 (Supplement 1): 5136.

https://doi.org/10.1182/blood-2018-99-112652

Published: 2018

Journal Articles

Niche Heterogeneity Impacts Evolution of Myeloproliferative Neoplasms Driven By the Same Oncogenic Pathway

Blood (2018) 132 (Supplement 1): 98.

https://doi.org/10.1182/blood-2018-99-113495

Published: 2018

Journal Articles

RAS-MPAK Pathway Signaling in Health and Disease

Qing Li, MD PhD

Blood (2018) 132 (Supplement 1): SCI-40.

https://doi.org/10.1182/blood-2018-99-109378

Published: 2018

Journal Articles

Gene Aberrations in Adult Patients with Ph-Negative ALL in the Czech Republic

Zuzana Vrzalova, PhD, Hana Jelinkova, Stepan Hrabovsky, Frantisek Folber, MD PhD, Cyril Salek, Jan Horacek, Marketa Zaliova, Jiri Stika, Martina Slavikova, Sarka Pospisilova, Michael Doubek, MD PhD

Blood (2018) 132 (Supplement 1): 4090.

https://doi.org/10.1182/blood-2018-99-118308

Published: 2018

Journal Articles

Signaling Pathways of Mutant IDH1 Independent of R-2-Hydroxyglutarate

Charu Gupta, Michelle Maria Araujo Cruz, PhD, Nidhi Jyotsana, PhD, Amit Sharma, PhD, Ramya Goparaju, PhD, Kerstin Görlich, Renate Schottmann, Eduard Struys, PhD, Erwin E Jansen, Felicitas Thol, MD, Arnold Ganser, MD, Michael Heuser, MD, Anuhar Chaturvedi, PhD

Blood (2018) 132 (Supplement 1): 2617.

https://doi.org/10.1182/blood-2018-99-110159

Published: 2018

Journal Articles

Aberrant Cytokine Production in Myelofibrosis Is Not Rectified By Ruxolitinib and Is Differentially Sensitive to Inhibition of JAK/STAT, MAP Kinase, and NFκB Signaling

Daniel A.C. Fisher, PhD, Cathrine Miner, Elizabeth Engle, PhD, Hengrui Hu, Taylor B. Collins, Amy Zhou, MD, Maggie J. Allen, Olga Malkova, Stephen T Oh, MD PhD

Blood (2018) 132 (Supplement 1): 3062.

https://doi.org/10.1182/blood-2018-99-119022

Published: 2018

NARROW

A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML

JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation

Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant–associated ALCL

HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms

Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade

Prognostic Impact of Chromosomal Abnormalities and Copy Number Alterations Among Adults with B-Cell Precursor Acute Lymphoblastic Leukaemia Treated on UKALL14

The Validation of the BCR/ABL1 -like Predictor across Laboratories Shows Reproducibility of Results

Progressive Down Regulation of JAK-STAT, Cell Cycle, and ABC Transporter Genes in CD34+/Lin- Cells of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients at Diagnosis Vs. 12 Months of Nilotinib Treatment Vs. Healthy Subjects

Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia

Integration of Genetic, Transcriptomic, and Immune Profiles Reveals Genomically-Distinct Populations in Low-Grade Lymphomas

HTLV-1 Dysregulates IL-6 and IL-10-JAK/STAT Signaling and Induces Leukemia/Lymphoma of Mature CD4+ T Cells with Regulatory T-Cell-like Signatures

Dual Driver Mutant BCR-ABL1-Negative Myeloid Neoplasms: Multicenter Clinicopathologic and Genomic Analysis

Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL

Autocrine LTA signaling drives NF-κB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma

A Case of CCDC6-RET Fusion Mutation in Adult Acute Lymphoblastic Leukemia (ALL), a Known Activating Mutation Unreported in ALL

Niche Heterogeneity Impacts Evolution of Myeloproliferative Neoplasms Driven By the Same Oncogenic Pathway

RAS-MPAK Pathway Signaling in Health and Disease

Gene Aberrations in Adult Patients with Ph-Negative ALL in the Czech Republic

Signaling Pathways of Mutant IDH1 Independent of R-2-Hydroxyglutarate

Aberrant Cytokine Production in Myelofibrosis Is Not Rectified By Ruxolitinib and Is Differentially Sensitive to Inhibition of JAK/STAT, MAP Kinase, and NFκB Signaling

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only